Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series A financing round, marking a significant step forward for the company. The round was led by Guozhong Capital, with additional investments from Lenovo Capital and Long Hill Capital. The funds will be directed towards accelerating clinical enrollment for Abrobo’s next-generation pan vascular intervention robot, constructing an intelligent vascular intervention robot technology platform, and enhancing the company’s talent team capabilities.
Expanding Clinical and Technological Capabilities
Founded in 2020, Abrobo is dedicated to the research and development, manufacturing, and sales of vascular interventional surgery robots. The company’s business scope spans a range of medical specialties, including cardiovascular intervention surgery, cerebrovascular intervention surgery, peripheral vascular intervention surgery, and tumor intervention surgery. This latest funding round follows an RMB120 million Pre-Series A financing round secured in March of the previous year, as reported by Fineline Info & Tech.
Strategic Investment and Future Growth
The strategic investment from Guozhong Capital, Lenovo Capital, and Long Hill Capital underscores the confidence in Abrobo’s potential to revolutionize the field of vascular interventional surgery with its robotic technology. With the new capital, Abrobo is poised to expand its clinical trials, enhance its technological platform, and strengthen its team, positioning the company for significant growth and innovation in the medical robotics sector.-Fineline Info & Tech
